Company intelligence / Profile preview
Microbiotica
Cambridge, England, United Kingdommicrobiotica.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
Microbiotica has two lead live biotherapeutic product candidates—MB097 for advanced melanoma (in combination with KEYTRUDA®) and MB310 for ulcerative colitis—both currently in Phase 1b studies. The company’s precision microbiome platform enables identification of specific gut bacteria associated with positive clinical outcomes. Data readouts from these trials are expected in 2025. The company has raised significant funding (£62M total) to advance its pipeline and expand into new indications.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Live biotherapeutic products (LBPs)live bacterial therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Genentech/Roche (up to $534M deal on IBD biomarkers/therapeutics)Cancer Research UK & Cambridge University Hospitals NHS Foundation Trust (immuno-oncology collaboration)University of Adelaide (collaboration on MB310 development)MSD/Merck & Co., Inc. supply agreement for KEYTRUDA® use in MB097 trial
Beyond the preview
Go deeper on Microbiotica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microbiotica.